Urinary nitrite and nitrate concentrations in patients with idiopathic persistent pulmonary hypertension of the newborn and effect of extracorporeal membrane oxygenation.

Persistent pulmonary hypertension of the newborn (PPHN) often requires extracorporeal membrane oxygenation (ECMO), during which time pulmonary vascular resistance gradually declines. Nitric oxide (NO) is a recently recognized pulmonary vasodilator, but its role in PPHN is unknown. We tested the hypothesis that the concentrations of the urinary metabolites of NO, i.e. nitrite and nitrate, are reduced in patients with PPHN and increase during ECMO as the PPHN resolves. Eight newborn infants with PPHN on ECMO were studied. Daily urinary concentrations of nitrite/nitrate were measured. We found that mean urinary concentrations of nitrite/nitrate were lower in patients with PPHN than in 47 controls without pulmonary disease (p < 0.005). Urinary nitrite/nitrate concentration showed an initial increase after initiation of ECMO. However, a decrease to concentrations still lower than controls occurred on the day before decannulation. We conclude that intrinsic NO production is significantly lower in patients with PPHN than in controls but increases with oxygenation. We speculate that decreased urinary NO metabolite concentrations imply a role for NO deficiency in the pathogenesis of PPHN.

Unusual metabolism of prostacyclin in infants with persistent septic pulmonary hypertension.

In urine of healthy man, the major metabolite of prostacyclin is 2,3-dinor-6-oxo-prostaglandin F1 alpha. The excretion rates of this compound as well as of 2,3-dinor-thromboxane B2, a major metabolite of thromboxane A2, in two newborns with septic persistent pulmonary hypertension were about 30- to 50-fold higher than the normal range (2,3-dinor-6-oxo-prostaglandin F1 alpha: 3-15 ng/h/1.73 m2; 2,3-dinor-thromboxane B2: 8-25 ng/h/1.73 m2). The ratios of 2,3-dinor-6-oxo-13,14-dihydro-prostaglandin F1 alpha/2,3-dinor-6-oxo-prostaglandin F1 alpha in these two infants were about 100% and 800%, respectively whereas in controls the excretion of the 13,14-dihydro metabolite was found to be about 10-25% of 2,3-dinor-6-oxo-prostaglandin F1 alpha. Thus in patients with septic persistent pulmonary hypertension and extremely high excretion rates of prostacyclin and thromboxane A2 metabolites, the pattern of metabolites differs from those of healthy man.